General Hospital
Effective: ___/___/20__
Review: ___/___/20__
Approved By: _________
Accreditation Alignment:
- CBAHI medication safety standards require secure, properly labeled medication storage within required temperature/humidity/light protection and restricted access.
- Joint Commission / JCI medication management standards emphasize safe storage, labeling, administration verification, and qualified personnel. (Joint Commission International)
- Perioperative medication safety guidance emphasizes sterile-field labeling, “no unlabeled containers,” and structured controls to prevent high-risk medication errors. (ECRI and ISMP)
1.0 PURPOSE
1.1 Purpose Statement
- 1.1.1 To ensure medications within OT scope are stored, secured, prepared, labeled, handled, and returned/wasted safely and consistently.
- 1.1.2 To prevent wrong-drug, wrong-concentration, wrong-route, and wrong-patient medication events through standardized sterile-field labeling, LASA segregation, high-alert controls, controlled drug accountability, temperature monitoring, expiry checks, and error reporting with a learning loop. (ECRI and ISMP)
- 1.1.3 To comply with OT-relevant requirements of CBAHI medication management standards (secure storage, appropriate conditions, organized labeling/arrangement, limited access) and with perioperative medication safety best practices.
2.0 SCOPE
2.1 Included
- 2.1.1 Medication storage areas inside OT (clean store, medication cupboard, medication refrigerator/freezer if present, controlled drug cabinet if present, satellite medication rooms under OT).
- 2.1.2 Sterile-field medications/solutions prepared in the operating room (syringes, bowls, cups, basins, irrigation additives, topical agents, dyes), including labeling requirements and transfer rules. (ECRI and ISMP)
- 2.1.3 High-alert medication controls when such medications are stored or handled in OT areas (e.g., concentrated electrolytes, heparin, insulin, neuromuscular blockers if stocked in OT, opioids if OT keeps controlled stock).
- 2.1.4 Controlled medications kept in OT (if applicable): receipt, storage, endorsed access, shift counts, discrepancy escalation, returns/wastage documentation, and auditing.
- 2.1.5 Medication error reporting from OT with feedback and corrective actions (OT QPS interface).
2.2 Excluded
- 2.2.1 Anesthesia department medication preparation/administration systems (e.g., anesthesia workstation syringes) — covered by anesthesia/pharmacy policy; however, sterile-field labeling and OT environment storage rules still apply to shared OR space.
- 2.2.2 Pharmacy sterile compounding procedures and clean room standards — governed by Pharmacy policy and applicable standards.
3.0 DEFINITIONS
- 3.1 LASA (Look-Alike/Sound-Alike): Medications with similar names or packaging that increase substitution risk; requires segregation and label enhancements.
- 3.2 High-Alert Medication (HAM): Medications with heightened risk of causing significant harm when used in error (e.g., concentrated electrolytes, insulin, anticoagulants, opioids); requires additional safeguards.
- 3.3 Sterile Field Medication Container: Any syringe, bowl, cup, basin, or bulb syringe on the sterile field containing a medication/solution. (ECRI and ISMP)
- 3.4 Independent Double-Check: A separate verification by a second qualified person without being guided by the first checker; applied to defined high-alert processes.
- 3.5 Beyond-Use/Expiry Time: The time after preparation when a product should not be used, as defined by manufacturer label, institutional policy, and risk assessment. (ECRI and ISMP)
4.0 POLICY STATEMENT
- 4.1 Medications stored in OT shall be secure, organized, properly labeled, and maintained within required temperature/humidity/light protection, with access restricted to authorized personnel.
- 4.2 No unlabeled medication containers are permitted in OT practice areas or on the sterile field; all prepared syringes/solutions/bowls/cups/basins must be labeled immediately after preparation and remain labeled until administration. (ECRI and ISMP)
- 4.3 LASA medications shall be risk-assessed and controlled through segregation, Tall-Man lettering (where adopted), shelf/bin labeling, and standardized selection processes.
- 4.4 High-alert medications within OT scope shall have enhanced safeguards including segregation, clear warning labeling, standardized concentrations, and independent double-checks where applicable.
- 4.5 Controlled medications kept in OT (if present) shall be stored in locked cabinets, dispensed/accessed only by authorized staff, documented for every receipt/use/return/wastage, and reconciled with discrepancy escalation pathways.
- 4.6 Expired/damaged medications shall be labeled and separated from usable stock until removal/destruction through pharmacy process; storage areas shall be inspected at least monthly by pharmaceutical care per policy.
- 4.7 Medication errors, near misses, and hazardous conditions shall be reported and reviewed with feedback and corrective actions using the OT QPS learning loop and perioperative medication safety improvement methods.
5.0 ROLES AND RESPONSIBILITIES
5.1 OT Director/Chair
- 5.1.1 Ensures governance, resources, and compliance monitoring for OT medication safety systems.
- 5.1.2 Escalates repeated safety risks to OTMC/QPS and Hospital Leadership.
5.2 OT Nurse Manager
- 5.2.1 Ensures implementation, staff training, and competency validation.
- 5.2.2 Ensures physical controls: locked storage, temperature logs, labeling supplies, LASA bins, high-alert labels, controlled drug accountability tools.
5.3 OT Charge Nurse (Shift Lead)
- 5.3.1 Ensures daily readiness: storage locked, temperature logs completed, expired separation bin used, sterile-field labels available.
- 5.3.2 Ensures immediate corrective actions when unsafe practices are observed (unlabeled syringe, unsecured meds, missing counts/discrepancies).
5.4 Pharmacy Representative / Pharmaceutical Care
- 5.4.1 Performs (or coordinates) monthly inspections of OT medication storage areas for availability, stock level, expiry date, and storage conditions per CBAHI expectations/policy.
- 5.4.2 Maintains formulary decisions, LASA list, high-alert list, and provides standardized labels/solutions where feasible.
5.5 Circulating Nurse (OR)
- 5.5.1 Ensures sterile-field medication transfer and labeling rules are followed; ensures unlabeled containers are not present. (ECRI and ISMP)
- 5.5.2 Coordinates safe medication availability and returns/wastage documentation for OT-managed meds.
5.6 Scrub Nurse/Technologist
- 5.6.1 Applies sterile-field labeling and “one medication at a time” transfer rules; confirms label correctness with circulating nurse where required. (ECRI and ISMP)
5.7 All Staff
- 5.7.1 Follow policy; report errors/near-misses/hazards; participate in audits and corrective actions.
6.0 PROCEDURES (SEC 10.1 – 10.7)
10.1 STORAGE, SECURITY, TEMPERATURE MONITORING
10.1.1 Medication Storage Area Standards
10.1.1.1 All OT medication storage areas shall be:
- a) clean, dry, organized, and clearly labeled
- b) protected from inappropriate heat, humidity, and light as required
- c) access-controlled (locked when not in use) and limited to authorized staff
10.1.1.2 Storage arrangement shall use organized segregation to reduce selection errors:
- a) separate by route (injectable vs topical vs irrigation additives)
- b) separate emergency items from routine items
- c) separate high-alert medications and LASA medications (see 10.3 and 10.4)
10.1.1.3 Multi-dose vials (if permitted) shall follow pharmacy policy for dating, storage, and discard after opening; OT shall not retain opened vials beyond policy.
10.1.2 Security Controls (Routine Medications)
10.1.2.1 Keys/access codes to medication cupboards are controlled:
- a) assigned to authorized roles
- b) not shared inappropriately
- c) documented if policy requires sign-in/out.
10.1.2.2 Medications shall not be left unattended on open counters in semi-restricted/restricted zones except during active case preparation with direct supervision.
10.1.3 Refrigerated / Frozen Storage and Temperature Monitoring
10.1.3.1 Refrigerators/freezers used for medications shall be dedicated (no food/drink), labeled, and locked where policy requires.
10.1.3.2 Temperature monitoring:
- a) Continuous digital monitoring is preferred when available; otherwise, minimum-maximum thermometer with manual documentation is required.
- b) Temperatures are recorded at least daily (or per hospital policy) and reviewed by charge nurse/manager.
- c) Acceptable ranges are defined by manufacturer requirements and Pharmacy policy; deviations trigger immediate action.
10.1.3.3 Out-of-range response algorithm:
- a) quarantine affected medications (do not use)
- b) notify charge nurse and pharmacy immediately
- c) document the event, duration if known, and corrective action
- d) pharmacy determines disposition (use/return/discard) based on stability guidance.
10.1.4 Monthly Storage Area Inspections (Pharmacy)
10.1.4.1 All OT medication storage areas are inspected at least monthly by pharmaceutical care to ensure proper storage conditions, stock levels, expiry checks, and organization.
10.1.4.2 Inspection findings generate corrective actions with deadlines and re-checks.
10.2 LABELING OF PREPARED SOLUTIONS/SYRINGES ON THE STERILE FIELD
10.2.1 Core Rule
10.2.1.1 Every medication or solution transferred to the sterile field and placed into a syringe/bowl/cup/basin must be labeled immediately after filling and must remain labeled up to the point of administration. (ECRI and ISMP)
10.2.1.2 Never label an empty syringe/bowl/cup/basin in anticipation of use (pre-labeling is prohibited). (ECRI and ISMP)
10.2.2 Label Type and Quality
10.2.2.1 Use sterile pre-printed labels on the sterile field whenever possible. (ECRI and ISMP)
10.2.2.2 When blank sterile labels are used:
- a) write clearly with smudge-proof marker
- b) avoid abbreviations unless approved
- c) ensure label adheres and remains legible during procedure.
10.2.3 Minimum Label Content (Sterile Field)
10.2.3.1 For practitioner-prepared syringes/solutions, labels shall include at minimum:
- a) medication/solution full name
- b) strength/concentration (or dose when applicable)
- c) initials/name of preparer
- d) preparation time and expiry/time when required by policy (especially when not used promptly or when stability is short) (ECRI and ISMP)
10.2.3.2 Color-coded class labels alone are not sufficient as the only identifier. (ECRI and ISMP)
10.2.4 “One at a Time” Transfer Rule
10.2.4.1 Transfer only one medication/solution at a time to the sterile field and label it immediately before any other medication/solution is transferred. (This prevents mix-ups when multiple unlabeled containers exist even briefly.) (aornjournal.onlinelibrary.wiley.com)
10.2.5 Verification at the Point of Transfer
10.2.5.1 When the circulating nurse hands medication/solution to the sterile field:
- a) scrub person reads the label on the source container aloud
- b) circulating nurse confirms verbally
- c) transfer occurs
- d) scrub person labels immediately and confirms label content (name + concentration).
10.2.5.2 For high-alert medications (see 10.4), apply independent double-check where defined.
10.2.6 Labeling of Irrigation Solutions and Additives
10.2.6.1 Any additive placed into an irrigation container must be labeled with:
- a) additive name
- b) total amount added
- c) final concentration where applicable
- d) time prepared
- e) preparer initials.
10.2.7 If a Container Is Found Unlabeled
10.2.7.1 An unlabeled syringe/bowl/cup/basin is treated as unknown and must be discarded immediately (do not attempt to “guess”). (ECRI and ISMP)
10.2.7.2 Report as a near-miss/hazard event under OT QPS.
10.3 LASA CONTROLS + SEGREGATION
10.3.1 LASA Risk Assessment and List
10.3.1.1 Pharmacy maintains a facility LASA list and reviews new additions; OT maintains an OT-specific LASA map for medications stocked in OT.
10.3.2 Storage Segregation Controls
10.3.2.1 LASA medications shall not be stored adjacent when possible; use:
- a) separated bins
- b) shelf dividers
- c) warning labels
- d) Tall-Man lettering on shelf labels where adopted.
10.3.2.2 LASA items shall be stored in a way that supports selection discipline:
- a) one bin = one medication/strength whenever feasible
- b) avoid “mixed bins” of multiple strengths.
10.3.3 Packaging and Procurement Controls
10.3.3.1 When feasible, pharmacy shall procure distinct packaging presentations or unit-dose labeling to reduce confusion; high-risk confusing presentations are escalated to P&T committee.
10.3.4 Selection and Preparation Controls
10.3.4.1 Staff shall read the full medication name and concentration before selection and again before opening/transfer to sterile field.
10.3.4.2 Where feasible, use barcode scanning outside sterile field; sterile-field labels may be exempt from machine-readable requirements but should still follow standardization principles. (ECRI and ISMP)
10.4 HIGH-ALERT MEDICATION HANDLING (OT DOUBLE-CHECK WHERE APPLICABLE)
10.4.1 High-Alert Medication (HAM) Governance
10.4.1.1 OT recognizes high-alert medications as those with heightened harm potential and implements additional safeguards, consistent with international definitions.
10.4.1.2 Pharmacy maintains the facility HAM list; OT identifies which HAMs are stocked/used under OT scope (e.g., concentrated electrolytes for irrigation? topical thrombin? heparinized saline? insulin in special situations?).
10.4.2 Concentrated Electrolytes Controls
10.4.2.1 Concentrated electrolyte solutions require strict controls including standardized limited concentrations, preference for premixed solutions where possible, and high-risk warning labeling.
10.4.2.2 Concentrated electrolytes should not be routinely available in patient care areas unless clinically necessary and approved; if stocked in OT, they must be:
- a) stored in a segregated, clearly labeled high-alert bin
- b) access-controlled
- c) used only for approved indications
- d) independently double-checked prior to preparation and prior to transfer to sterile field (where applicable).
10.4.3 Independent Double-Check Rules (OT)
10.4.3.1 OT applies independent double-check for defined high-alert steps when OT is responsible for preparation/transfer, such as:
- a) preparation of a high-alert solution or dilution
- b) addition of high-alert additives to irrigation
- c) preparation of high-risk local anesthetic concentrations for surgeon use if policy defines it as high-alert.
10.4.3.2 Double-check elements:
- a) drug name
- b) concentration/strength and volume
- c) final concentration if diluted
- d) labeling completeness (10.2)
- e) intended use/site/route.
10.4.3.3 Both checkers sign/initial the High-Alert Double-Check form (Appendix E).
10.4.4 Restricted Storage and “Do Not Stock” Decisions
10.4.4.1 OT shall not stock unnecessary HAM items; stock decisions require pharmacy approval and risk assessment.
10.5 CONTROLLED MEDICATIONS KEPT IN OT (ENDORSEMENT, DISCREPANCY ESCALATION)
(Applies only if OT maintains controlled stock outside anesthesia/pharmacy-controlled systems.)
10.5.1 Storage and Access
10.5.1.1 Controlled medications are stored in a locked controlled drug cabinet with restricted access.
10.5.1.2 Access is limited to authorized personnel endorsed by OT leadership and pharmacy policy.
10.5.2 Receipt and Inventory
10.5.2.1 Receipt from pharmacy is documented with:
- a) date/time
- b) drug name/strength/quantity
- c) lot/expiry if required
- d) signatures (sender/receiver).
10.5.3 Administration/Use Documentation
10.5.3.1 Each dose removed is documented immediately per controlled drug record (paper/electronic), including patient identifier (as permitted), dose, time, and staff signature.
10.5.4 Shift Counts and Reconciliation
10.5.4.1 Controlled drug counts are performed:
- a) at shift start and end
- b) after any controlled drug access event if policy requires
- c) after discrepancy suspicion.
10.5.4.2 Count is performed by two authorized staff and documented.
10.5.5 Discrepancy Escalation Pathway
10.5.5.1 Any discrepancy triggers immediate actions:
- a) stop further dispensing from that cabinet (quarantine)
- b) re-count and verify records
- c) notify OT charge nurse and pharmacy immediately
- d) document discrepancy and actions
- e) escalate to OT manager and hospital leadership per policy if unresolved.
10.5.5.2 Discrepancies are reviewed in QPS for system vulnerabilities (access control, documentation quality, workflow design).
10.6 RETURNS, WASTAGE DOCUMENTATION, EXPIRY CHECKS
10.6.1 Returns (Unused, Unopened Medications)
10.6.1.1 Unused unopened medications may be returned to pharmacy only if:
- a) integrity maintained
- b) temperature conditions maintained (cold chain not broken)
- c) return permitted by pharmacy policy.
10.6.1.2 Returned items are documented with date/time, item details, reason, and signatures.
10.6.2 Wastage
10.6.2.1 Medication wastage is documented to prevent diversion and ensure traceability:
- a) drug name/strength/amount wasted
- b) reason for wastage
- c) witness signature (especially for controlled meds)
- d) disposal method per pharmacy policy.
10.6.3 Expiry Checks and Removal of Expired/Damaged Items
10.6.3.1 OT performs routine expiry checks:
- a) daily visual check of high-risk areas (emergency boxes, anesthesia interface drawers under OT control, sterile field additive stocks)
- b) weekly/monthly structured expiry inspection per local plan
- c) pharmacy monthly inspection includes expiry verification.
10.6.3.2 Expired and damaged medications shall be labeled and separated from usable stock until removed and destroyed through pharmacy process.
10.6.4 Cold Chain Returns and Quarantine
10.6.4.1 Any medication with uncertain storage condition (temperature excursion, door left open) is quarantined and pharmacy decides disposition.
10.7 MEDICATION ERROR REPORTING & LEARNING LOOP
10.7.1 What Must Be Reported
10.7.1.1 Report all medication events within OT scope, including:
- a) wrong drug/wrong concentration selection caught before use (near miss)
- b) unlabeled syringe/bowl/cup/basin found
- c) LASA selection confusion
- d) high-alert double-check failures
- e) controlled drug discrepancies
- f) administration errors and adverse drug events.
10.7.1.2 Perioperative medication errors are recognized as significant sources of harm; structured guidance exists to address perioperative/procedural medication safety gaps and implement action plans. (psnet.ahrq.gov)
10.7.2 Immediate Containment
10.7.2.1 Protect the patient first:
- a) stop administration
- b) maintain the source container and label(s) as evidence
- c) notify surgeon/clinical lead and pharmacy as required
- d) provide clinical response per treating team.
10.7.3 Investigation Level and Corrective Action
10.7.3.1 OT QPS lead triages events:
- a) quick review for low-risk near misses
- b) mini-RCA for trends and high-risk near misses
- c) formal RCA for serious harm events.
10.7.3.2 Corrective actions prioritize strong system changes:
- a) standardization of labels and availability of pre-printed sterile labels (ECRI and ISMP)
- b) segregation/bin redesign for LASA
- c) removal of unnecessary high-alert stock in OT
- d) redesign of transfer workflow (“one at a time” rule, read-back) (aornjournal.onlinelibrary.wiley.com)
- e) competency refresh and direct observation.
10.7.4 Feedback and Learning Loop
10.7.4.1 OT provides monthly de-identified learning summaries:
- a) what happened (pattern)
- b) what changed (system fix)
- c) what to watch (new barrier)
- d) audit result after change.
10.7.4.2 Safety improvement is measured using compliance audits and event trend reduction.
7.0 DOCUMENTATION / CONTROLLED RECORDS
- 7.1 Medication storage temperature logs (room + refrigerator/freezer)
- 7.2 Monthly pharmacy inspection reports and corrective action tracker
- 7.3 Sterile-field medication labeling audit forms (ECRI and ISMP)
- 7.4 High-alert medication double-check forms
- 7.5 Controlled drug register/count sheets/wastage records (if applicable)
- 7.6 Returns and wastage documentation
- 7.7 Medication incident reports and QPS review minutes.
8.0 TRAINING AND COMPETENCY
8.1 Initial orientation and annual refreshers shall include:
- 8.1.1 storage/security and temperature excursion response
- 8.1.2 sterile-field labeling rules, “no unlabeled containers,” one-at-a-time transfer (ECRI and ISMP)
- 8.1.3 LASA controls and selection discipline (compasshcc.org)
- 8.1.4 high-alert safeguards and concentrated electrolyte controls
- 8.1.5 controlled drug accountability and discrepancy escalation (if applicable)
- 8.1.6 reporting and learning loop expectations. (psnet.ahrq.gov)
8.2 Competency validation methods:
- a) direct observation (sterile-field labeling practice)
- b) documentation review (double-check form completion, temperature logs)
- c) scenario drills (unlabeled syringe found; LASA confusion; temperature excursion; controlled drug discrepancy).
9.0 MONITORING, AUDIT, AND KPIs
9.1 Minimum Audits
- 9.1.1 Sterile-field labeling audit (monthly sample): correct content, immediate labeling, no pre-labeling, no unlabeled containers. (ECRI and ISMP)
- 9.1.2 LASA storage audit (quarterly): segregation, shelf labeling, removal of mixed bins.
- 9.1.3 High-alert compliance audit (monthly/quarterly): segregation, double-check completion, removal of unnecessary concentrated electrolytes.
- 9.1.4 Temperature log compliance and excursion handling audit (monthly).
- 9.1.5 Controlled drug reconciliation audit (monthly) if applicable.
9.2 KPIs (Minimum Set)
- 9.2.1 % sterile-field containers correctly labeled (target ≥ 95%) (ECRI and ISMP)
- 9.2.2 Number of “unlabeled container” events per 1,000 cases (target: 0; near-miss reporting encouraged) (ECRI and ISMP)
- 9.2.3 LASA-related near misses (trend)
- 9.2.4 High-alert double-check compliance %
- 9.2.5 Temperature excursion count and response time (trend)
- 9.2.6 Controlled drug discrepancy rate (if applicable).
10.0 NONCOMPLIANCE (CRITICAL)
10.1 Critical noncompliance includes:
- 10.1.1 Unlabeled syringe/bowl/cup/basin present on sterile field (ECRI and ISMP)
- 10.1.2 Pre-labeling empty containers on the sterile field (ECRI and ISMP)
- 10.1.3 Storage areas left unsecured / access uncontrolled
- 10.1.4 High-alert medication stored without segregation/warning label or used without defined double-check where required
- 10.1.5 Expired/damaged medications not separated/labeled pending removal
10.2 Critical noncompliance triggers immediate correction, documentation, and escalation to OT manager and QPS.
11.0 REFERENCES (ENGLISH)
-
11.1 ISMP — Guidelines for Safe Medication Use in Perioperative and Procedural Settings (sterile-field labeling expectations; minimum label content; preprinted sterile labels preferred). (ECRI and ISMP)
-
11.2 ISMP — Medication Safety Self Assessment® for Perioperative Settings (supports sterile label availability and periop controls). (ECRI and ISMP)
-
11.3 WHO Patient Safety Solution Control of Concentrated Electrolyte Solutions (standardization, warning labels, premixed solutions).
-
11.4 Joint Commission (MM chapter FAQ) Medication labeling requirements located in MM standards and procedure container labeling linked to patient safety goals. (jointcommission.org)
-
11.5 CBAHI (Istitlaa) — Medication Safety Standards secure storage with proper temperature/humidity/light protection and restricted access.
-
11.6 CBAHI (Istitlaa) — Monthly inspection of medication storage areas; expired/damaged meds separated until removal/destruction.
-
11.7 JCI Hospital Standards (Standards-only PDF excerpt) medication management and qualified administration/verification requirements (MMU). (Joint Commission International)
-
11.8 ISMP Targeted Medication Safety Best Practices for Hospitals (additional system-level risk controls and best practices). (online.ecri.org)